TB Diagnostics Market Size, Share, Trends and Forecast, 2026–2034

Market Overview

The global TB diagnostics market is experiencing steady growth as healthcare providers increasingly prioritize early tuberculosis detection, accurate diagnosis, and identification of drug-resistant infections. Molecular diagnostic technologies, culture-based testing, sputum microscopy, and immunological assays play an important role in identifying Mycobacterium tuberculosis and supporting timely treatment decisions. Growing demand for rapid testing and expanded screening programmes is encouraging the adoption of advanced diagnostic solutions across hospitals, laboratories, and community healthcare facilities.

According to Straits Research, the global TB diagnostics market was valued at USD 1.48 billion in 2025 and is projected to increase from USD 1.56 billion in 2026 to USD 2.41 billion by 2034. The market is expected to register a CAGR of 5.56% during the forecast period. North America held the largest regional share in 2025, while Asia Pacific is anticipated to record the fastest growth through 2034.

Report: http://straitsresearch.com/report/tb-diagnostics-market

Market Size and Forecast

The global TB diagnostics market is projected to experience consistent expansion between 2026 and 2034, supported by increasing requirements for early diagnosis, drug-resistance testing, and broader screening coverage. The market is expected to grow from USD 1.56 billion in 2026 to USD 2.41 billion by 2034, representing a CAGR of 5.56%.

North America accounted for 36.4% of the global market in 2025, reflecting its leading regional position. By test type, nucleic acid testing (NAT) represented the largest segment with a 30.6% share. Hospitals and diagnostic laboratories dominated the end-user segment, accounting for 52.8% of the market. Reference laboratories are projected to be the fastest-growing end-user segment, registering a CAGR of 6.52% during the forecast period.

Market Drivers

Rising Need for Drug-Resistance Testing

The increasing requirement to identify drug-resistant tuberculosis is supporting demand for advanced diagnostic technologies. Tests that detect resistance to commonly used TB medicines help healthcare providers select appropriate treatment regimens and reduce delays in patient management. Molecular platforms such as GeneXpert MTB/RIF support early detection by identifying tuberculosis bacteria and rifampicin resistance. Growing clinical requirements for resistance identification are encouraging the adoption of molecular assays, drug-susceptibility tests, and specialized laboratory supplies.

Expansion of TB Screening and National Elimination Programmes

High numbers of undiagnosed TB cases and targeted screening requirements among high-risk populations are increasing demand for diagnostic services. People living with HIV, household contacts of TB patients, and individuals with conditions such as diabetes require screening and diagnostic evaluation. At the same time, national TB elimination programmes are expanding procurement of diagnostic equipment, laboratory supplies, and testing services. These initiatives are supporting wider testing coverage across hospitals, community health centres, and diagnostic laboratories.

Buy Now: http://straitsresearch.com/report/tb-diagnostics-market/buy-now

Market Challenges

Need for Greater Laboratory Testing Capacity

Expanding TB diagnosis requires additional laboratory facilities, diagnostic equipment, trained personnel, and reliable consumable supplies. Rising testing workloads increase the need for investments in laboratory infrastructure and operational capacity. Gaps in these resources can make it difficult for healthcare providers to expand diagnostic coverage and process increasing numbers of samples efficiently.

Accessibility of Advanced Diagnostic Technologies

The deployment of advanced molecular diagnostic platforms requires solutions that are reliable, affordable, and suitable for different healthcare settings. Resource-limited facilities may require simplified procedures and cost-effective testing systems to expand access. These requirements create a need for manufacturers to improve diagnostic accessibility while maintaining test accuracy and reliability.

Market Opportunities

Growth of Near-Patient Molecular Testing

Point-of-care molecular diagnostic platforms present opportunities to expand TB testing beyond centralized laboratories. Cartridge-based nucleic acid amplification tests can detect Mycobacterium tuberculosis DNA and selected drug-resistance markers through automated sample processing. Compact systems designed for community clinics and peripheral healthcare facilities can support decentralized testing and earlier treatment decisions.

Expansion of Drug-Resistance Detection

Growing demand for multidrug-resistant and extensively drug-resistant TB testing is creating opportunities for advanced molecular assays and targeted sequencing technologies. These platforms can help laboratories identify a broader range of resistance markers and support more informed treatment selection. Diagnostic manufacturers can strengthen their market positions by expanding drug-resistance testing capabilities.

Market Segmentation

The TB diagnostics market is segmented by test type and end-user.

By Test Type

Nucleic acid testing (NAT) dominated the market with a 30.6% share in 2025. Its leading position is supported by high diagnostic accuracy, rapid detection capabilities, and molecular identification of tuberculosis infections. NAT is also projected to be the fastest-growing test type, registering a CAGR of 7.48% during 2026–2034. Increasing adoption of molecular diagnostic technologies and demand for timely identification of TB and drug resistance are supporting this growth.

Other test types include skin test or Mantoux test (TST), blood test or serology test, smear microscopy, culture-based tests, radiography tests, and other diagnostic methods.

By End-User

Hospitals and diagnostic laboratories held the largest market share of 52.8% in 2025. Their dominance reflects their role in TB screening, diagnosis, and patient management, supported by established laboratory infrastructure, high patient volumes, and access to multiple diagnostic methods.

Reference laboratories are expected to register the fastest growth, with a projected CAGR of 6.52% during 2026–2034. Increasing demand for specialized testing, confirmatory diagnosis, and advanced detection of drug-resistant tuberculosis is supporting this segment.

Other end-users include physician's office laboratories and academic and research facilities.

Regional Analysis

North America

North America dominated the global TB diagnostics market with a 36.4% share in 2025. Continued investment in early detection, molecular diagnostics, and laboratory testing supports regional demand.

In the U.S., the CDC's 2030 targets include reducing TB incidence to 1.48 cases per 100,000 people, achieving 95% reporting of positive TB NAAT results within six days, and 100% reporting of initial drug-susceptibility results. These priorities support demand for rapid molecular diagnostics and advanced laboratory testing.

Canada's commitment to achieving TB pre-elimination across the country by 2035 and eliminating TB among Inuit communities across Inuit Nunangat by 2030 is expected to support expanded screening and early diagnosis.

Asia Pacific

Asia Pacific is projected to be the fastest-growing regional market, registering a CAGR of 7.12% during 2026–2034. Expanding diagnostic infrastructure, national screening initiatives, and molecular testing programmes are supporting regional growth.

India's plans to add 1,000 AI-enabled handheld chest X-ray devices to its TB screening network, alongside broader molecular testing initiatives, are expected to strengthen diagnostic coverage. China's National TB Prevention and Control Plan (2024–2030) also supports demand through targets for increased contact screening, pathogen confirmation, and drug-resistance testing. In Japan, expanded pre-entry TB screening and national incidence-reduction targets are expected to support diagnostic demand.

Europe

Europe accounted for 27.6% of the global TB diagnostics market in 2025. Regional demand is supported by screening initiatives and early-detection priorities. The U.K. aims to reduce TB incidence by 90% by 2035, while its national TB Action Plan promotes wider access to WHO-recommended rapid diagnostic tests. In Germany, active case finding and contact investigations remain important priorities for improving early diagnosis and preventing transmission.

Key Players

The TB diagnostics market is moderately fragmented, with established in-vitro diagnostics companies, molecular technology providers, medical device manufacturers, and specialized infectious disease diagnostic companies. The leading five companies are estimated to collectively account for approximately 35–40% of the global market, although their exact combined share is not publicly disclosed.

Major companies operating in the market include:

Thermo Fisher Scientific Inc.
Becton, Dickinson and Company
F. Hoffmann-La Roche Ltd.
QIAGEN N.V.
Hologic, Inc.
bioMérieux SA
Oxford Immunotec Ltd.
Cepheid, Inc.

Competition is shaped by diagnostic accuracy, test sensitivity and specificity, product reliability, regulatory approvals, distribution networks, affordability, and relationships with hospitals, laboratories, and public health organizations.

Recent Industry Developments

In May 2026, QIAGEN announced plans to advance its QuantiFERON latent TB testing portfolio through a fully automated Sample-to-Insight workflow and an AI-enabled TB progression risk-stratification tool, supported by an automation partnership with Inpeco.

In March 2026, the World Health Organization issued its first recommendations for near-point-of-care molecular TB tests, tongue-swab specimens, and sputum pooling, expanding the diagnostic approaches suitable for decentralized TB detection.

In July 2025, the NIIDAN-TB pilot project was launched in Nagpur with AI-assisted mobile TB screening vans and a molecular diagnostic laboratory for drug-resistance testing.

Conclusion

The global TB diagnostics market is expected to maintain steady growth through 2034, supported by increasing demand for early tuberculosis detection, drug-resistance testing, and expanded screening programmes. Nucleic acid testing will remain an important growth segment because of its rapid detection capabilities and molecular diagnostic applications. Hospitals and diagnostic laboratories will continue to represent a major end-user base, while reference laboratories are expected to record the fastest growth.

North America currently leads the market, whereas Asia Pacific offers strong growth potential through expanding diagnostic infrastructure and national TB control initiatives. Advances in near-patient molecular testing and broader drug-resistance detection are expected to create further opportunities for market participants.

Request Sample: http://straitsresearch.com/report/tb-diagnostics-market/request-sample